RESEARCH TRIANGLE PARK, N.C., Oct. 21, 2024 -- It is with deep sadness that Pappas Capital announces the passing of Dr. Ernest Mario, Senior Venture Partner and one of the founders...
CardioDx Announces Results of Study Demonstrating the Benefits of the Corus CAD Gene Expression Test Use in an African American Patient Population
News | 10. 20. 2014
CardioDx
- Patients with Low Corus CAD Scores Had a 95% Decreased Rate of Referral for Advanced Cardiac Testing Versus Patients with Elevated Corus CAD Scores -
REDWOOD CITY, Calif. – [October 20, 2014] - CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, today announced the presentation of the study, “The Use of a Gene Expression Score Showed Clinical Utility in Evaluating African Americans Presenting with Symptoms Suggestive of Obstructive Coronary Artery Disease in a Primary Care Practice,” at the 36th Annual North American Meeting of the Society for Medical Decision Making, taking place from Oct. 18-22 in Miami.
